Skip to main content

Table 3 Means QOL scores over time

From: Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)

 

PC group (n = 34), mean (SD)

VGD group (n = 34), mean (SD)

Assessment time

Baseline

6 week

12 week

18 week

Baseline

6 week

12 week

18 week

FACT-G

        

   Physical well-being (7 items)

21.8 (5.3)

16.9 (7.1)

16.1 (5.4)

12.8 (5.7)

21.4 (5.3)

19.1 (6.7)

20.2 (6.2)

20.2 (5.1)

   Social/family well-being (7 items)

19.7 (4.7)

19.7 (5.0)

18.9 (6.2)

19.4 (5.2)

18.9 (6.0)

19.6 (4.9)

20.1 (5.1)

17.2 (6.0)

   Emotional well-being (6 items)

16.1 (5.1)

15.6 (5.9)

15.5 (6.4)

13.6 (5.6)

14.1 (5.8)

16.3 (5.5)

16.8 (5.1)

16.4 (5.5)

   Functional well-being (7 items)

17.5 (6.7)

14.9 (6.3)

15.2 (6.6)

13.1 (5.4)

16.2 (6.9)

17.2 (6.5)

19.2 (6.0)

16.4 (7.2)

   FACT-G total (27 items)

73.0 (15.4)

65.1 (17.5)

63.4 (17.4)

57.1 (14.7)

69.0 (12.8)

70.3 (16.7)

74.6 (15.7)

68.9 (16.5)

FACT-L

        

   Lung cancer subscale (7 items)

19.0 (5.1)

19.3 (3.8)

19.3 (4.8)

18.8 (4.2)

18.9 (3.7)

18.9 (6.0)

20.3 (4.5)

20.4 (5.1)

   Trial outcome index-lung (21 items)

57.6 (12.5)

51.2 (13.3)

49.9 (13.8)

44.6 (10.6)

56.2 (10.8)

55.1 (15.9)

59.7 (14.2)

57.0 (14.8)

FACT-Taxane

        

   Neurotoxicity (11 items)

40.3 (4.1)

30.0 (9.4)

24.3 (9.3)

16.0 (7.2)

39.6 (5.6)

37.4 (7.2)

38.9 (5.5)

37.0 (7.0)

   Taxane (16 items)

59.9 (4.3)

47.5 (12.0)

41.0 (11.7)

30.4 (9.9)

59.1 (6.8)

56.5 (8.9)

58.3 (6.1)

55.4 (9.3)

   Trial outcome index-taxane (30 items)

98.9 (13.7)

78.9 (21.2)

70.9 (17.4)

55.8 (15.9)

96.7 (11.9)

92.5 (18.0)

97.7 (15.1)

91.8 (16.8)

FACIT-Sp

        

   Spirituality (12 items)

30.3 (9.8)

30.1 (9.6)

28.3 (11.8)

27.2 (12.4)

28.4 (11.5)

29.6 (9.8)

28.3 (11.4)

30.0 (9.4)